anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVE: The most recent edition of the International Clinical Practice Guideline for the Prevention and Treatment of Pressure Ulcers/Injuries was released in 2019. Shortly after, in 2020, the first edition of the SECURE Prevention expert panel report, focusing on device-related pressure ulcers/injuries, was published as a special issue in the Journal of Wound Care. A second edition followed in 2022. This article presents a comprehensive summary of the current understanding of the causes of pressure ulcers/injuries (PU/Is) as detailed in these globally recognised consensus documents.
METHOD: The literature reviewed in this summary specifically addresses the impact of prolonged soft tissue deformations on the viability of cells and tissues in the context of PU/Is related to bodyweight or medical devices.
RESULTS: Prolonged soft tissue deformations initially result in cell death and tissue damage on a microscopic scale, potentially leading to development of clinical PU/Is over time. That is, localised high tissue deformations or mechanical stress concentrations can cause microscopic damage within minutes, but it may take several hours of continued mechanical loading for this initial cell and tissue damage to become visible and clinically noticeable. Superficial tissue damage primarily stems from excessive shear loading on fragile or vulnerable skin. In contrast, deeper PU/Is, known as deep tissue injuries, typically arise from stress concentrations in soft tissues at body regions over sharp or curved bony prominences, or under stiff medical devices in prolonged contact with the skin.
CONCLUSION: This review promotes deeper understanding of the pathophysiology of PU/Is, indicating that their primary prevention should focus on alleviating the exposure of cells and tissues to stress concentrations. This goal can be achieved either by reducing the intensity of stress concentrations in soft tissues, or by decreasing the exposure time of soft tissues to such stress concentrations.
The research project is a pilot study to assess the effects of a multi-component intervention in increasing physical activity among persons with depression. Individuals meeting inclusion/exclusion criteria will be enrolled in the 12-week intervention. Intervention components will include self-monitoring, Active Living counseling, and facility access. Blood samples will be collected at baseline. Assessments (anxiety, stress, sleep) and sample collection will also occur at 2 time points during the intervention (Weeks 7 and 13). Changes in physical activity will be assessed using Fitbits to measure weekly minutes of moderate/vigorous activity.
PURPOSE OF THE STUDY: Iatrogenic ureteral injury (IUI) is a rare but formidable complication of any abdominal or pelvic surgery. The aim of this study was to describe the epidemiology of IUI in colorectal surgery in the Basse-Normandie region over the period 2004-2022, as well as to review the literature on the management of this complication.
MATERIALS AND METHODS: This multicenter retrospective analysis of clinical data (medical records and operative reports) concerned 22 patients (13 men and 9 women) who suffered an IUI during colorectal surgery between 2004 and 2022. Ureteral resections for oncological purposes and endoluminal instrumental injuries (post-ureteroscopy) were excluded from the study. We also carried out a review of the literature concerning the incidence of IUI in colorectal surgery.
RESULTS: The incidence of IUI was 0.27% over the study period (22 ureteral injuries out of 8129 colorectal procedures). Colorectal cancer and sigmoid diverticulitis were the dominant surgical indications (85% of cases). Proctectomy and left colectomy were the most performed resection procedures (75% of cases). Surgery was scheduled in 68% of cases. The approach was open laparotomy in 59% and laparoscopy in 41% of cases. The IUI involved the left ureter in 63% of cases and the pelvic ureter in 77% of cases. Conservative endoscopic treatment by insertion of a double-J catheter stent had a success rate of 87.5%. Surgical repairs consisting of re-implantation techniques and uretero-ureteral anastomosis had a success rate of 75%. The nephrectomy rate was 13.6% (3/22) and the mortality rate 9% (2/22). A literature review identified sixteen studies, where the incidence of IUI varied from 0.1 to 4.5%.
FINDINGS: IUI occurring during colorectal surgery is a rare occurrence but remain a formidable complication. No means of prevention has proven its effectiveness to date, but guidance devices using illuminated ureteral catheters or dyes seem to constitute a promising approach. Injuries to the left pelvic ureter are the most common, and the majority can be treated endoscopically if diagnosed early.
Subjects who have greater than 50% necrosis as determined by MRI, Endoscopic Ultrasound (EUS), or direct transluminal endoscopic imaging of the collection. This stratification group will be randomized to either the double pigtail plastic stent or the AXIOS metal stent.
The present invention relates to a dental nanofiber chip equipped with medication and a method for manufacturing the same. Nanofibers having an average diameter of 10-1000nm interweave in a network type and constitute a nanofiber chip having a transverse size of 1-20mm, a longitudinal size of 1-20mm, and a thickness of 0.1-5mm. Medication is mounted on surfaces and pores of the nanofibers, which exist inside the nanofiber chip. The nanofibers are composed of a bio-degradable polymer or titanium oxide. A nanofiber chip manufactured by the present invention comprises fibers having a nano-sized diameter, thereby having a very large specific surface area, and the network structure thereof enables easy attachment to a wounded area. The contained medication can be discharged continuously for a predetermined period of time, thereby making the nanofiber chip usable as a disinfectant, an antibiotic, etc.
This is a Phase 3, double-blind, randomized, placebo-controlled study of KER-050 where participants will be randomized and enter the Primary Phase of the Double-blind Treatment Period. Participants will be randomly assigned in a 2:1 ratio to receive either KER-050 or placebo subcutaneously (SC) every 4 weeks (Q4W). Participants will be stratified according to their RS status (RS-positive versus non-RS) and baseline transfusion burden (LTB versus HTB) during the Screening Period. The Primary Phase of the Double-blind Treatment Period will last up to 24 weeks. Study visits will occur approximately every 2 weeks during the first 24 weeks and approximately every 4 weeks thereafter. For participants to remain on double-blind treatment, they must meet the criteria outlined in the MDS disease assessment criteria every 24 weeks. Based on the outcome of the Week 24 MDS disease assessment, participants will either continue in the Extension Phase of the Double-blind Treatment Period or will be discontinued from treatment and proceed to End of Treatment and then into the Safety Follow-up Period.
All participants will received piperonyl butoxide-treated LLINs (PBO-LLINs) at Stage 1, however, Stage 1 intervention is not effective. All participants will received PBO-LLINs plus an enhanced intervention at Stage 2, i.e., annual IRS using Kenya Government recommended insecticides.
Synergistic therapies for the treatment of vitiligo are provided. The major therapies for the treatment of vitiligo- a pigmentary disorder characterized by patchy depigmentation of skin are Psoralens plus UV-A, steroids, basic fibroblast growth factor (bFGF) peptide lotion or surgical procedures. Psoralens plus UV-A is effective in about 50% of cases, steroids are limitedly effective only in fast spreading cases of vitiligo and often reoccurs on stoppage of treatment. Surgical treatment is the last resort for vitiligo therapy, when all other therapies failed. It is limitedly effective. Basic fibroblast growth factor peptide(s) lotion was developed as a new mode of therapy for the treatment of vitiligo It went through successfully various phases of clinical trials in India and is allowed to be marketed by the drug controller general (India). It is effective in 80% of stable vitiligo and in segmental vitiligo. Here data are provided and demonstrated that combinatorial treatment of vitiligo by local application of bFGF peptide(s) lotion in association with psoralens and UV-A, or steroids or surgical procedures produce synergistic response and that the rate of re-pigmentation increases synergistically and more efficacious results are obtained than with any of them alone. Any combinatorial therapy comprising the local application of bFGF peptide lotion on the vitiligo patch in combination with any other therapy for the treatment of vitiligo appears to act synergistically.
Allysine, a pivotal biomarker in fibrogenesis, has prompted the development of various radioactive imaging probes. However, fluorogenic probes targeting allysine remain largely unexplored. Herein, by leveraging the equilibrium between the nonfluorescent spirocyclic and the fluorescent zwitterionic forms of rhodamine-cyanine hybrid fluorophores, we systematically fine-tuned the environmental sensitivity of this equilibrium toward the development of fluorogenic probes for fibrosis. The trick lies in modulating the nucleophilicity of the ortho-carboxyl group, which is terminated with a hydrazide group for allysine conjugation. Probe B2 was developed with this strategy, which featured an N-sulfonyl amide group and exhibited superior fibrosis-to-control imaging contrast. Initially presenting as nonfluorescent spirocyclic aggregates in aqueous solutions, B2 displayed a notable fluorogenic response upon conjugation with protein allysine through its hydrazide group, inducing deaggregation and switching to the fluorescent zwitterionic form. Probe B2 outperformed the traditional Masson stain in imaging contrast, achieving an about 260-2600-fold ratio for fibrosis-to-control detection depending on fibrosis severity. Furthermore, it demonstrated efficacy in evaluating antifibrosis drugs. Our results emphasize the potential of this fluorogenic probe as an alternative to conventional fibrosis detection methods. It emerges as a valuable tool for antifibrosis drug evaluation.
Objective: To analyze the clinical features of postpartum hepatitis flares in pregnant women with hepatitis B virus (HBV) infection. Methods: A retrospective study was conducted. Patients who met the enrollment criteria were included. Liver function and HBV virology tests were collected from pregnant women with chronic HBV infection at delivery, 6, 24, 36, and 48 weeks after delivery through the hospital information and test system. Additionally, antiviral therapy types and drug withdrawal times were collected. Statistical analysis was performed on all the resulting data. Results: A total of 533 pregnant women who met the inclusion criteria were included, with all patients aged (29.5±3.7) years old. A total of 408 cases received antiviral drugs during pregnancy to interrupt mother-to-child transmission. There was no significant difference in the levels of alanine aminotransferase (ALT, z = -1.981, P = 0.048), aspartate aminotransferase (AST, z = -3.956, P < 0.001), HBV load (z = -15.292, P < 0.001), and HBeAg (z = -4.77, P < 0.001) at delivery in patients who received medication and those who did not. All patients ALT, AST, total bilirubin, direct bilirubin, and albumin showed an upward trend within six weeks after delivery. A total of 231 cases developed hepatitis within 48 weeks after delivery. Among them, 173 cases first showed ALT abnormalities within six weeks postpartum. Conclusion: Hepatitis flare incidence peaked six weeks after delivery or six weeks after drug withdrawal in pregnant women with chronic HBV infection.
The invention belongs to the technical field of biological medicines, and particularly relates to application of BAP18 in endocrine therapy resistance of breast cancer. The application of a targeted inhibitor of BAP18 in preparing a medicine for treating breast cancer, wherein the targeted sequence of the inhibitor is SEQ ID No. 1. Experiments show that BAP18 can promote the endocrine drug resistance of breast cancer, and participate in the tumor drug resistance process in a tamoxifen mouse model. BAP18 has potential drug resistance function in breast cancer endocrine drugs, and is used for preparing BAP18 small molecule inhibitor, siRNA or the discovery that miRNA is generated by inhibiting BAP18 transcription so as to achieve the functions of treating clinical breast cancer and relieving breast cancer endocrine treatment resistance. BAP18 only plays a role in promoting cancer progression in the process of cancer occurrence and development, BAP18 is up-regulated in most tissues of breast cancer patients, the inhibition of BAP18 can effectively reduce side effects brought by other drugs, and the treatment of the combination with an inhibitor can effectively increase the clinical treatment effect.
CC100 (3 single increasing doses by mouth). Dosing will occur every 2 to 7 days for a study duration of 5 to 15 days from the 1st dose.
The present invention relates to a method for the production of a culture, e.g. an organoid culture of ovarian cancer or cancer precursor cells, particularly of high grade serous ovarian carcinoma cells. By means of this method, an organoid culture of ovarian cancer or cancer precursor cells and a biobank comprising a plurality of different organoid cultures of ovarian cancer or cancer precursor cells may be generated. Further, a culture medium suitable for the long-term culture of ovarian cancer or cancer precursor cells is provided. Furthermore, use of the organoid culture and the biobank for medical applications, e.g. in the field of diagnostics, and therapy and in the field of drug screening is described.
To provide timed-releasable granules of high versatility that can sufficiently suppress the elution of an active ingredient until a lag time and allows the active ingredient to be quickly eluted after a lapse of the lag time.SOLUTION: Granules are prepared by coating a core containing an active ingredient with a coating layer containing a water-insoluble polymer and an inorganic compound and having a mass content of the inorganic compound being higher than that of the water-insoluble polymer. The granules take, in an elution test paddle method, three minutes or longer for 5% of the active ingredient to be eluted and 90% or more of the active ingredient to be eluted for 30 minutes. The water-insoluble polymer may contain a (meth)acrylic polymer having an ammonio methacrylate unit. The mass content of water-swellable substance in the core may be less than 30 mass%. The core may be substantially free of the water-swellable substance. The inorganic compound may be one selected from the group consisting of talc, light silicic anhydride, hydrous silicon dioxide, and aluminum aluminometasilicate.SELECTED DRAWING: None
Encouraging and educational text messages and animations were created based on barriers to breastfeeding found during preceding focus groups and a baseline survey. Messages were written in English and translated into Spanish, with back-translation to ensure accuracy. Mothers who plan to or are already breastfeeding will be recruited and invited to participate in the study in the post-partum ward after delivery at Public Hospital Roatán. Written informed consent will be obtained. Three animated videos will be shown to mothers at enrollment providing information regarding breastfeeding technique, breastfeeding encouragement and general breastfeeding information. SMS messages will start at time of enrollment and continue through six months after enrollment. Messages will be delivered through Telerivet, an SMS interactive platform designed to send the educational and motivational messages to mothers' cell phones.

The intervention group will be polled when infants turn two months, four months, and six months regarding their infant feeding practices through Telerivet via SMS messaging. The primary outcome of this study is exclusive breastfeeding at 2 months of age, as compared to the exclusive breastfeeding rate obtained in our baseline cross sectional survey. Exclusive breastfeeding will be defined as giving only mother's breastmilk in the 24 hours preceding the interview. Mothers will also be asked if they are breastfeeding at all, age of infant when they last gave breast milk, the incidence of diarrheal illness in the past two weeks, and any other foods / liquids given to infant.
Preventing childhood obesity from early life is considered essential. However, evidence from recent systematic reviews has highlighted inconsistent results and limited effectiveness of preconception and pregnancy lifestyle interventions regarding offspring weight outcomes and adiposity. Therefore, to improve our understanding regarding the mixed success of these early life interventions, we conducted a scoping review examining intervention complexity, process evaluation components, and authors' statements. Eligible articles (preconception or pregnancy lifestyle trials with offspring data beyond 1 month of age) were identified by searching databases (PubMed, Embase, and CENTRAL), previous reviews, and performing CLUSTER searches. The Intervention Complexity Assessment Tool for Systematic Reviews (iCAT_SR) was used to evaluate intervention complexity. A thematic analysis provided insight into process evaluation components and authors' interpretations. Finally, an expert consultation on the results was conducted. We identified 40 eligible publications corresponding to 27 trials. Only two trials started before conception. Potential reasons for interventions' limited success included the late intervention initiation, short intervention duration, and insufficient sample size. Few studies reported process evaluations and included stakeholder involvement, which are essential according to the expert group. We discuss current limitations and outline suggestions for future interventions in this field of research.
1. A dosage form comprising a gelatin-encapsulated composition comprising sertraline, or a pharmaceutically acceptable salt thereof, and a water immiscible vehicle. 2. A dosage form as defined in Claim 1, which decreases Tmax time, by which the maximum concentration of sertraline in blood plasma is reached , at least 0.5 hr in comparison with oral forms with direct deliverance. 3. A dosage form as defined in Claim 1, which decreases Tmax time, by which the maximum concentration of sertraline in blood plasma is reached , at least one hour in comparison with oral forms with direct deliverance. 4. A dosage form as defined in Claim 1, containing 10 mgA to 300 mgA of sertraline. 5. A dosage form as defined in Claim 4, containing 10 mgA to 250 mgA of sertraline. 6. A dosage form as defined in Claim 5, containing 10 mgA to 100 mgA of sertraline. 7. A dosage form as defined in Claim 1, wherein said vehicle comprises a mono-, di-, or triglyceride, or a mixture thereof. 8. A dosage form as defined in Claim 7, wherein the acyl chain(s) of said mono-, di-, or triglyceride average 4-18 carbons in length. 9. A dosage form as defined in Claim 8, wherein the acyl chain(s) of said mono-, di-, or triglyceride average 6-14 carbons in length. 10. A dosage form as defined in Claim 1, wherein said vehicle is liquid at 37 degree C. 11. A dosage form as defined in Claim 1, wherein said vehicle comprises a vegetable oil. 12. A dosage form as defined in Claim 11, wherein said vegetable oil is selected from corn oil, peanut oil, sesame oil, olive oil, castor oil, coconut oil, cottonseed oil, soybean oil, or safflower oil. 13. A dosage form as defined in Claim 1, wherein said vehicle comprises a surfactant or emulsifier. 14. A dosage form as defined in Claim 13, wherein said surfactant or emulsifier is selected from polysorbate-80, nonylphenoxypolyoxyethylene, dioctyl sodium sulfosuccinate, PEG-6-glycerylmonooleate, or PEG-6-glyceryllinoleate. 15. A dosage form as defined in Claim 1, wherein said vehicle comprises a fatty acid. 16. A dosage form as defined in Claim 15, wherein said fatty acid is selected from caprylic acid, capric acid, lauric acid, oleic acid, or linoleic acid. 17. A dosage form as in Claim 1, wherein said dosage form comprises a liquid ester of a short chain alcohol and acid. 18. A dosage form as in Claim 17, wherein said ester is selected from the propylene glycol esters of caprylic and/or capric acids. 19. A dosage form as in Claim 1, wherein said vehicle additionally comprises an alcohol. 20. A dosage form as in Claim 19, wherein said alcohol is polyethyleneglycol, glycerin, ethanol, or propyleneglycol. 21. A dosage form as defined in Claim 1, which decreases precipitation of sertraline in a chloride ion containing use environment relative to a comparison dosage form made with a water-miscible vehicle. 22. A method of treating an illness amenable to treatment with sertraline, comprising administering to a person in need of such treatment a dosage form as defined in Claim 1.
The RIETE Registry pretends the improvement of care of patients with thromboembolic disease. Very often the investigators pose serious doubts on how to manage a specific patient. Sometimes because it is a patient with thrombocytopenia, a pregnant woman, a patient with a recent cerebral bleeding or cerebral metastasis, a patient with gastroduodenal ulcer or hepatic cirrhosis. There is no clinical evidence about how the investigators should manage these patients and the investigators have to individualize its management. The bibliography available is not of much help. Only if the investigators have a database with a sufficient number of cases, they may be able to make evidence based decisions.

This database on the Internet will allow the investigators to consult and obtain an immediate response when taking care of a patient who needs an individualized management. After introducing the patient the investigators will automatically obtain the data of all patients with similar clinical profiles. And this will help the investigators to identify high-risk patients and thus facilitate them preventing possible future complications.
The invention discloses an oral herbal medicine for treating the waist injuries and a use method thereof. The medicine is prepared from 14 herbal medicines and swine chine in proportion, wherein tubers and aboveground parts of Polygonum chinense L. var. thunbergianum Meisn, roots and leaves of Cynoglossum zeylanicum (Vahl) Thunb. ex Lehm, Eomecon chionantha, Sabia schumanniana Diels and Ardisia japonica serve as monarch medicines and have effects on stimulating menstrual flow and activating blood circulation, dissipating blood stasis and removing accumulation, and eliminating swelling and promoting diuresis to eliminate dampness; Polypodiodes subamoena, BrouSSoneti a kazinoki Sueb, Elaeagnus henryi and Ophiophagus Hannah serve as minister medicines and have effects on clearing away heat and toxic materials, dispelling wind and eliminating dampness, and connecting bones and stopping pain; semen cassiae soap, Disporum sessile, Sinocalycanthus chinensis and swine chine serve as assistant medicines and have effects on tonifying kidney and strengthening tendons and muscles, enriching blood and replenishing essence, and replenishing qi to invigorate the spleen; Cynanchum chekiangense and the whole plant of Clematis meyeniana Walp serve as guide medicines and have effects on regulating qi and removing dampness, and clearing and activating the channels and collaterals; in addition, millet wine serves as an ingredient added to enhance the efficacy of the medicine. Finally, a dose of medicine capable of clearing and activating the channels and collaterals, breaking stasis and eliminating swelling, reinforcing kidney and strengthening bones, and dispelling wind and promoting diuresis to eliminate dampness is formed, and therefore the effect of treating the waist injuries is achieved. The medicine has the advantages of being low in cost, capable of treating both symptoms and root causes, high in cure rate, free of drug dependence and free of toxic and side effects.